岳改英,李景,解欣然,周旭升,李江敏子,谷玉红,易京红

• 1:首都医科大学附属北京中医医院
• 2:北京市房山区韩村河镇社区卫生服务中心
• 3:北京市中医研究所

摘要(Abstract)：

目的观察糖心宁对糖尿病心肌病大鼠心肌组织ROCK、JNK及P38MAPK蛋白表达的影响,探讨其对ROCK-MAPK信号通路的作用机制。方法采用链脲佐菌素制备糖尿病心肌病大鼠模型,40只雄性SD大鼠随机分为空白组、模型组、法舒地尔组、糖心宁高剂量组、糖心宁等效剂量组各8只。空白组及模型组灌服等量清洁饮用水,法舒地尔组给予法舒地尔腹腔注射,糖心宁组灌服中药糖心宁。给药8周后处死大鼠,计算左心室肥厚指数,检测血糖、血脂水平;HE染色观察心肌细胞形态学变化;免疫组化法检测心肌组织ROCK、JNK、P38MAPK蛋白表达情况。结果给药8周末,模型组大鼠空腹血糖、甘油三酯明显高于空白组(均P<0.05);与模型组比较,法舒地尔组、糖心宁高剂量组、糖心宁等效剂量组甘油三酯水平明显降低(均P<0.05),但空腹血糖未见明显变化(均P>0.05)。模型组大鼠心肌肥厚指数明显高于空白组(P<0.05);与模型组比较,法舒地尔组、糖心宁高剂量组、糖心宁等效剂量组心肌肥厚指数均低于模型组(P<0.05)。HE染色光镜下观察,空白组大鼠心肌细胞肌节完整,肌丝、线粒体排列比较整齐。模型组大鼠心肌细胞肿胀,肌丝排列稀疏,肌丝断裂、溶解,心肌出现大面积玻璃样变性及坏死。糖心宁高剂量组、糖心宁等效剂量组、法舒地尔组大鼠心肌细胞肿胀,肌丝排列均较模型组有明显好转。与空白组大鼠比较,模型组大鼠的ROCK1蛋白表达显著增加(P<0.05),而ROCK2蛋白表达未见明显增加(P>0.05)。与模型组大鼠比较,法舒地尔组、糖心宁高剂量组、糖心宁等效剂量组的ROCK1蛋白表达受到显著抑制(P<0.05),ROCK2蛋白表达未见明显改变(P>0.05)。与法舒地尔组比较,糖心宁高剂量组明显抑制ROCK1蛋白表达(P<0.05),而糖心宁等效剂量组则并不明显(P>0.05)。与空白组大鼠比较,模型组大鼠的JNK、P38MAPK蛋白表达均显著增加(P<0.05),与模型组大鼠比较,法舒地尔组、糖心宁高、等效剂量组大鼠JNK、P38MAPK蛋白表达均明显受到抑制(P<0.05)。结论糖心宁能减轻糖尿病心肌病大鼠的心室重构,其机制可能与抑制ROCK-MAPK信号通路有关。

关键词(KeyWords)： 糖尿病心肌病;心室重构;糖心宁;ROCK-MAPK信号通路

Abstract:

Keywords:

基金项目(Foundation): 首都中医药研究专项一般项目(15ZY15);; 首都医科大学附属北京中医医院“育苗计划”院级课题(2014YM-07)

作者(Author): 岳改英,李景,解欣然,周旭升,李江敏子,谷玉红,易京红

参考文献(References)：

• [1]Hamby RI,Zoneraich S,Sherman L,et al.Diabetic cardiomyopath[J].JAMA,1974,229(13):1749-1754.
• [2]衡先培.糖尿病微血管病辨证论治[M].北京:人民卫生出版社,2007:378-495.
• [3]张春虹,臧伟进,徐静,等.建立糖尿病心肌病动物模型方法的实验研究[J].卫生研究,2006,35(6):707-711.
• [4]Liu Wen-qi,Dai Hong-yan,Xing Ming-qing,et al.Establishiment of animal models of diabetic cardiomyopathy[J].Chinese Journal of Tissue Engineering Research,2015,19(27):4265-4270.
• [5]LI Q,XU Y,LI X,et al.Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction:role of TGF-betal-TAKl[J].Toxicol Lett,2012,211(2):91-97.
• [6]GUO P,WUC,Masaki T,et al.Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats[J].Pharmazie,2011,66(9):716-719.
• [7]WANG N,GUAN P,ZHANG JP,et al.Fasudil hydrochlofide hydrate,a Rho-kinase inhibitor,suppresses isoproterenol-induced heart failure in rats via JNK and ERKl/2 pathways[J].J Cell Biochem,2011,112(7):1920-1929.
• [8]Takeshima H,Kobayashi N,Koguchi W,et al.Cardioprotective effect of a combination of Rho-kinase inhibitor and p38MAPK inhibitor on cardiovascular remodeling and oxidative stress in dahl rats[J].J Atheroscler Thromb,2012,19(4):326-336.
• [9]ZHOU H,LI YJ,WANG M,et al.Involvement of Rho A/ROCKin myocardial fibrosis in a rat model of type 2 diabetes[J].Acta Pharmaeol Sin,2011,32(8):999-1008.
• [10]SHI J,ZHANG YW,YANG Y,et al.ROCKl plays an essential role in the transition from cardiac hypertrophy to failure in mice[J].J Mol Cell Cardiol,2010,49(5):819-828.
• [11]YANG X,LI Q,LIN X,et al.Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiledcoil protein kinase 1[J].FASEB J,2012,26(5):2105-2116.
• [12]Vahebi S,Kobayashi T,Warren CM,et al.Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin[J].Circ Res,2005,96(7):740-747.
• [13]Zhang L,Ding WY,Wang ZH,et al.Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis,reducing apoptosis and enhancing autophagy[J].J Transl Med,2016,14:109.
• [14]Li CJ,Lv L,Li H,et al.Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid[J].Cardiovasc Diabetol,2012,11:73.
• [15]Fierro C,Novoa U,Gonzalez V,et al.Simultaneous Rho Kinase inhibition in circulating leukocytes and in cardiovascular tissue in rats with high angiotensin converting enzyme levels[J].Int J Cardiol,2016,215:309-17.
• [16]魏执真.糖心宁治疗糖尿病性心脏病的临床及实验研究[J].北京中医,1998,17(4):59-60.